Cargando…
Phase II study of gemcitabine in patients with advanced pancreatic cancer.
The efficacy and safety of gemcitabine at a starting dose of 800 mg m2 administered once a week for 3 weeks with 1 week's rest was investigated in chemonaive patients with advanced and/or metastatic pancreatic cancer. Of 34 patients, 32 were evaluable for efficacy, 20 patients had metastatic st...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1996
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074288/ https://www.ncbi.nlm.nih.gov/pubmed/8554969 |